AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 122 min read$PFE

BOURLA ALBERT purchased $1.0M of PFE

BOURLA ALBERT (Chairman & CEO) purchased 38,000 shares of PFIZER INC (PFE) at $26.34 ($1.00M total) on 2026-08-12.

Original reporting
SEC EDGAR · BOURLA ALBERT
Published Aug 12, 2026, 8:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PFE
Neutral
medium confidence
Mentioned
$PFE
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFENeutralLow
01

Why it matters

The newest fact is the CEO’s open-market purchase size, price, and total value. Traders may treat it as a small sentiment input, not a standalone catalyst.

02

Market read

A $1.0M CEO open-market buy is a modest, sentiment-oriented signal with limited direct implications for near-term fundamentals.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still does not disclose the insider’s rationale or whether other material company events are occurring concurrently.

Relevance 7/10Novelty 6/10Timing: filed 2026-08-12, after-hours SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for Pfizer, filed on 2026-08-12.

Company-level read

Ticker impact

$PFENeutralMedium confidence
Context

Pfizer Form 4 shows CEO Albert Bourla bought 38,000 shares on 2026-08-12 at $26.34, totaling about $1.0M.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than earnings or guidance-driven.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is a single insider purchase without accompanying company guidance, contract, or regulatory development.

Market effects

Sector

Minimal; insider buying in a large pharma name typically does not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine, tax-related, or opportunistic around liquidity needs, and they do not guarantee near-term outperformance.

Key entities

  • issuer
    Pfizer Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Albert Bourla

    Chairman and CEO who purchased 38,000 shares on 2026-08-12.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PFE insider trading history →

Related articles

SEP 4
$PFEMedAI 8/10

Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

Pfizer (PFE) stock has declined 19.19% over five years, resulting in a 6% dividend yield. The company paid $9.77 billion in dividends in 2025, with a thin cash cushion. CEO Albert Bourla assured dividend maintenance but ruled out near-term hikes. Q2 2026 adjusted EPS was $0.77, beating estimates, with full-year guidance of $2.80-$3.00.

aol.com3 min
SEP 4
$PFEHighAI 8/10

19 vaccine approved by US FDA

The US FDA approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for adults 65+ and high-risk individuals 5-64. The approval is based on clinical, real-world, and manufacturing data. The vaccine targets the XFG variant and will be available in the US from autumn 2026.

pmlive.com2 min
SEP 2
$MRNAMed

Updated COVID-19 vaccines are coming this fall. Will insurance cover them?

The FDA approved updated COVID-19 vaccines from Moderna, Pfizer, and Sanofi for the fall season. Health insurers, per AHIP, will cover these vaccines, as required by the Affordable Care Act. Uninsured individuals may access free vaccines through state or federal programs. The vaccines target specific high-risk groups, with recommendations from the AAFP and CDC.

abcnews.com3 min
SEP 2
$PFEHighAI 9/10

FDA Approves Updated COVID-19 Vaccines for 2026-2027

The FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax targeting the JN.1-lineage XFG variant. Approvals cover high-risk populations, including adults 65+ and those with underlying conditions. Pfizer and Moderna's mRNA vaccines and Novavax's protein-based vaccine are now authorized for distribution.

respiratory-therapy.com2 min